Nuvation Bio Inc.
6.52USD
-0.0900 (-1.36%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $-0.09▲ | $-0.11 | 0 | 1 |
| Next quarter | $-0.09 | $-0.09 | 0 | 1 |
| Current year | $-0.29▼ | $-0.28 | 0 | 1 |
| Next year | $-0.02▲ | $-0.06 | 0 | 1 |
Beat in 1 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $-0.12 | $-0.15 | -0.03 (-25.2%) |
| 2026-03-31 | $0.05 | $0.04 | -0.01 (-23.6%) |
| 2025-12-31 | $-0.05 | $-0.09 | -0.04 (-91.1%) |
| 2025-09-30 | $-0.15 | $-0.14 | +0.01 (+7.0%) |
78 ratings from 15 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Cantor Fitzgerald | Initiated | Overweight | — | Aug 21, 2026 |
| JP Morgan | Initiated | Overweight | $13 | Aug 18, 2026 |
| RBC Capital | Maintained | Outperform | $19 $20 | Aug 7, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $17 $21 | Jul 27, 2026 |
| Wedbush | Reiterated | Outperform | $11 | Jul 23, 2026 |
| RBC Capital | Maintained | Outperform | $20 $19 | Jul 7, 2026 |
| Truist Securities | Maintained | Buy | $12 $13 | Jul 7, 2026 |
| RBC Capital | Reiterated | Outperform | $20 | May 5, 2026 |
| Wedbush | Reiterated | Outperform | $11 | May 5, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $17 | May 5, 2026 |
| Wedbush | Reiterated | Outperform | $11 | Apr 16, 2026 |
| Wedbush | Reiterated | Outperform | $11 | Apr 2, 2026 |
| Wedbush | Reiterated | Outperform | $11 | Mar 27, 2026 |
| UBS | Maintained | Neutral | $10 $7 | Mar 3, 2026 |
| RBC Capital | Maintained | Outperform | $12 $13 | Mar 3, 2026 |
| Wedbush | Reiterated | Outperform | $11 | Feb 10, 2026 |
| RBC Capital | Maintained | Outperform | $9 $12 | Jan 21, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $18 $17 | Jan 12, 2026 |
| UBS | Initiated | Neutral | $10 | Jan 7, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $10 $18 | Dec 11, 2025 |
| HC Wainwright & Co. | Reiterated | Buy | $10 | Dec 1, 2025 |
| Truist Securities | Initiated | Buy | $11 | Nov 24, 2025 |
| Citizens | Maintained | Market Outperform | $8 $10 | Nov 20, 2025 |
| B. Riley Securities | Initiated | Buy | $12 | Nov 19, 2025 |
| RBC Capital | Maintained | Outperform | $7 $8 | Nov 4, 2025 |
44 filings from 12 insiders · 9 buy / 7 sell over 6m
Officers and directors of NUVB, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| HATTERSLEY GARYOfficer | Sell | 100.0k | $7.09 | $709k | Aug 19, 2026 |
| HATTERSLEY GARYOfficer | Exercise | 100.0k | $1.87 | $187k | Aug 19, 2026 |
| SAUVAGE PHILIPPEChief Financial Officer | Exercise | 40.0k | $1.97 | $87k | Jul 15, 2026 |
| MARKEL STACYOfficer | Exercise | 125.0k | $1.74 | $229k | Jun 23, 2026 |
| SAUVAGE PHILIPPEChief Financial Officer | Exercise | 47.7k | $2.17 | $103k | Jun 23, 2026 |
| WENTWORTH KERRY AOfficer | Exercise | 63.0k | $2.93 | $185k | Jun 23, 2026 |
| SAUVAGE PHILIPPEChief Financial Officer | Sell | 47.7k | $6.01 | $286k | Jun 23, 2026 |
| WENTWORTH KERRY AOfficer | Sell | 63.0k | $6.02 | $379k | Jun 23, 2026 |
| MARKEL STACYOfficer | Sell | 125.0k | $6.03 | $753k | Jun 23, 2026 |
| MASHAL ROBERTDirector | Buyindirect | 25.0k | $4.73 | $118k | Jun 9, 2026 |
| LIU DONGFANGOfficer | Exercise | 50.0k | $1.94 | $97k | Apr 17, 2026 |
| WENTWORTH KERRY AOfficer | Exercise | 36.8k | $2.93 | $108k | Apr 17, 2026 |
| LIU DONGFANGOfficer | Sell | 50.0k | $5.02 | $251k | Apr 17, 2026 |
| WENTWORTH KERRY AOfficer | Sell | 36.8k | $5.01 | $184k | Apr 17, 2026 |
| WENTWORTH KERRY AOfficer | Exercise | 200.0k | $1.87 | $381k | Apr 6, 2026 |
| WENTWORTH KERRY AOfficer | Sell | 200.0k | $4.52 | $904k | Apr 6, 2026 |
| MAKUNJE MOSESOfficer | Grant | 50.8k | — | — | Feb 27, 2026 |
| LIU DONGFANGOfficer | Exercise | 150.0k | $2.93 | $440k | Dec 1, 2025 |
| LIU DONGFANGOfficer | Sell | 150.0k | $7.82 | $1.17M | Dec 1, 2025 |
| LIU DONGFANGOfficer | Exercise | 20.0k | $3.61 | $72k | Nov 26, 2025 |
No analyst notes on NUVB yet.
Analyst Ratings
10 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 3 | 7 | 1 | 0 | 0 | Buy1.82 |
| 1 mo ago | 2 | 7 | 1 | 0 | 0 | Buy1.90 |
| 2 mo ago | 2 | 7 | 1 | 0 | 0 | Buy1.90 |